US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

REX CRYPTO EQUITY PREMIUM INCOME ETF

40.02

-0.0218-0.05%

Post-market: 39.95-0.0679-0.17%17:16 EDT

Volume:29.31K

Turnover:1.17M

Market Cap:- -

PE:- -

High:40.17

Open:40.09

Low:39.85

Close:40.04

52wk High:52.16

52wk Low:31.35

Shares:- -

Float Shares:1.57M

Volume Ratio:1.14

T/O Rate:1.87%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Dyadic Revenue Jumps 150% in Fiscal Q2

DYAI: CEPI Grants Recognize C1

Zacks Small Cap Research

Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion

Dyadic International receives a funding award from CEPI

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CEPI"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CEPI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CEPI\",,,,,undefined,":{"symbol":"CEPI","market":"US","secType":"STK","nameCN":"REX CRYPTO EQUITY PREMIUM INCOME ETF","latestPrice":40.0179,"timestamp":1755288000000,"preClose":40.0397,"halted":0,"volume":29314,"hourTrading":{"tag":"盘后","latestPrice":39.95,"preClose":40.0179,"latestTime":"17:16 EDT","volume":42,"amount":1695.1574,"timestamp":1755292589184},"delay":0,"floatShares":1565000,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-0.0218,"latestTime":"08-15 16:00:00 EDT","open":40.09,"high":40.1671,"low":39.85,"amount":1173579.75123,"amplitude":0.00792,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1755504000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":40.0397,"sharesOutstanding":1565000,"nav":40.03,"aum":62646950,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":40.02,"preClose":40.0397,"latestTime":"09:16 EDT","volume":132,"amount":5283.15216,"timestamp":1755263776639},"postHourTrading":{"tag":"盘后","latestPrice":39.95,"preClose":40.0179,"latestTime":"17:16 EDT","volume":42,"amount":1695.1574,"timestamp":1755292589184},"volumeRatio":1.13978,"impliedVol":0.4329,"impliedVolPercentile":0.9677},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CEPI\",,,,,undefined,":{"symbol":"CEPI","floatShares":1565000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.13978,"shares":0,"dividePrice":0,"high":40.1671,"amplitude":0.00792,"preClose":40.0397,"low":39.85,"week52Low":31.35,"pbRate":"--","week52High":52.16,"institutionHeld":0,"latestPrice":40.0179,"eps":0,"divideRate":0,"volume":29314,"delay":0,"ttmEps":0,"open":40.09,"prevYearClose":46.52,"prevWeekClose":39.6164,"prevMonthClose":39.8814,"prevQuarterClose":40.29,"fiveDayClose":39.6164,"twentyDayClose":41.7678,"sixtyDayClose":39.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CEPI\",params:#limit:5,,,undefined,":[{"date":"2025-07-29","symbol":"CEPI","amount":1.45635,"announcedDate":"2025-07-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-29","defaultRemindTime":1753795800000,"name":"REX CRYPTO EQUITY PREMIUM INCOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-30","payableDate":"2025-07-29","currency":"USD","dateTimestamp":1753761600000,"payDate":"2025-07-30"},{"date":"2025-06-24","symbol":"CEPI","amount":1.3797,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"REX CRYPTO EQUITY PREMIUM INCOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-25","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-06-25"},{"date":"2025-05-29","symbol":"CEPI","amount":1.3881,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-29","defaultRemindTime":1748525400000,"name":"REX CRYPTO EQUITY PREMIUM INCOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-30","payableDate":"2025-05-29","currency":"USD","dateTimestamp":1748491200000,"payDate":"2025-05-30"},{"date":"2025-04-29","symbol":"CEPI","amount":1.3286,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-29","defaultRemindTime":1745933400000,"name":"REX CRYPTO EQUITY PREMIUM INCOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-30","payableDate":"2025-04-29","currency":"USD","dateTimestamp":1745899200000,"payDate":"2025-04-30"},{"date":"2025-03-25","symbol":"CEPI","amount":1.45915,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"REX CRYPTO EQUITY PREMIUM INCOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-26","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CEPI\",market:\"US\",,,undefined,":[{"executeDate":"2025-01-28","recordDate":"2025-01-28","paymentDate":"2025-01-29","value":1.69835,"currency":"USD"},{"executeDate":"2025-02-25","recordDate":"2025-02-25","paymentDate":"2025-02-26","value":1.57775,"currency":"USD"},{"executeDate":"2025-03-25","recordDate":"2025-03-25","paymentDate":"2025-03-26","value":1.45915,"currency":"USD"},{"executeDate":"2025-04-29","recordDate":"2025-04-29","paymentDate":"2025-04-30","value":1.3286,"currency":"USD"},{"executeDate":"2025-05-29","recordDate":"2025-05-29","paymentDate":"2025-05-30","value":1.3881,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CEPI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CEPI\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2559982805","title":"Dyadic Revenue Jumps 150% in Fiscal Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2559982805","media":"Motley Fool","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559982805?lang=en_us&edition=fundamental","pubTime":"2025-08-14 05:52","pubTimestamp":1755121920,"startTime":"0","endTime":"0","summary":"Revenue  jumped 150.5% year over year to $0.97 million, beating GAAP revenue estimates by 61.2% due to milestone and grant income.Net operating loss  narrowed to $1.73 million from $2.04 million in Q2 2024, with significant cost discipline in general and administrative expenses.No recurring commercial product revenue yet; commercial launches for key life sciences and nutrition products are projected for late 2025.","market":"nz","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fcdn.content.foolcdn.com%2Fimages%2F1umn9qeh%2Fproduction%2F2e67fde4d458002cf59f26acf09dd58f97b62ce0-1024x1024.png&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fcdn.content.foolcdn.com%2Fimages%2F1umn9qeh%2Fproduction%2F2e67fde4d458002cf59f26acf09dd58f97b62ce0-1024x1024.png&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/data-news/2025/08/13/dyadic-revenue-jumps-150-in-fiscal-q2/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["CEPI"],"gpt_icon":0},{"id":"2522783532","title":"DYAI: CEPI Grants Recognize C1","url":"https://stock-news.laohu8.com/highlight/detail?id=2522783532","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522783532?lang=en_us&edition=fundamental","pubTime":"2025-03-27 23:23","pubTimestamp":1743088980,"startTime":"0","endTime":"0","summary":"Dyadic International Inc.  announced 2024 results and listed a number of accomplishments that will bring both product and grant revenue in the next months. We are most excited about the partnership with Proliant Health. Dyadic signed a deal in June with Proliant which has so far generated multiple milestone payments while preparing for commercialization of animal-free recombinant albumin products manufactured using C1. We anticipate albumin product sales in 2Q:25. Later this year, product sales from non-animal dairy enzymes with partner Inzymes are forecast to flow through the door. Several grant awards have also been announced, including a Gates Foundation award and two Coalition for Epidemic Preparedness Innovation  awards, which are also backed by the Gates Foundation.Dyadic released 2024 operational and financial results in a press release on March 26th, 2025, filed its Form 10-K with the SEC and held a conference call with investors. Since the last quarterly update, Dyadic partici","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dyai-cepi-grants-recognize-c1-152300804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CEPI","DYAI","BK4139"],"gpt_icon":0},{"id":"2521765797","title":"Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion","url":"https://stock-news.laohu8.com/highlight/detail?id=2521765797","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521765797?lang=en_us&edition=fundamental","pubTime":"2025-03-24 14:00","pubTimestamp":1742796000,"startTime":"0","endTime":"0","summary":"Saint Herblain , March 24, 2025 – Valneva SE , a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France’s Island of La Réunion with its vaccine IXCHIQ. In agreement and with support from the local public health agency, the Agence Régionale de Santé La Réunion, Valneva will provide 40,000 doses starting early April, with an option to provide more, through distribution agreements with the Island’s wholesalers. This supply of doses, paid for by the French authorities, is in line with the recommendation of France’s national public health agency, the Haute Autorité de Santé , to prioritize for vaccination adults aged 65 and over, with co-morbidities. IXCHIQ remains available for purchase in France .Valneva is focused on expanding the vaccine’s label and access. In the third quarter of 2024, the Company expanded its partnership with the Coalition for Epidemic Preparedness 8, with support from the EU Horizon Europe p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-responds-french-government-call-060000542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDC","INRLF","SII","BK4585","BK4139","BK4588","HAS","VALN","BK4190","BK4566","CEPI","BK4135"],"gpt_icon":0},{"id":"2520456407","title":"Dyadic International receives a funding award from CEPI","url":"https://stock-news.laohu8.com/highlight/detail?id=2520456407","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520456407?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:40","pubTimestamp":1742474420,"startTime":"0","endTime":"0","summary":"Dyadic International (DYAI) announced that it has received a funding award from CEPI to use C1 to accelerate the development of protein-based vacci...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dyadic-international-receives-a-funding-award-from-cepi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dyadic-international-receives-a-funding-award-from-cepi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","DYAI","CEPI"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CEPI\",params:#limit:6,delay:false,,,undefined,":[]}}